Shows
Pharma Market Access Insights - from Petauri EvidenceNavigating US payer evidence needs to optimise market accessSend us a textWhat clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their ex...2024-11-2757 min
Pharma Market Access Insights - from Petauri EvidenceBest practice RWE approaches to support economic modelling for HTASend us a textHow can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Prof...2024-11-2059 min
Pharma Market Access Insights - from Petauri EvidenceNHS winter planning 2024–25 – Engaging with NHS decision-makers through Autumn to ChristmasSend us a textHow is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.Jo and Karen discuss:How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Place and ICB levelSpecific challenges and pressures facing the NHS now and in...2024-11-181h 02
Pharma Market Access Insights - from Petauri EvidenceNHS primary care panel – the GP Contract and Operational Planning GuidanceSend us a textWhat can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:- Jack Wagstaff (Place Leader, Surrey Heartlands Health and Care Partnership, Chie...2024-09-101h 02
Pharma Market Access Insights - from Petauri EvidenceMarket access and reimbursement in Canada – changes at CADTHSend us a textWhat do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:The market access landscape in CanadaUpcoming changes at CADTHWhat Canadian payers expect from your val...2024-06-2047 min
Pharma Market Access Insights - from Petauri EvidenceRare Disease market access in the MENA and Nordic regionsSend us a textWhere will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar, our Global Market Access team compare and contrast access opportunities and challenges for r...2024-05-1059 min
Pharma Market Access Insights - from Petauri EvidenceHow does funding flow in NHSE Regions?Send us a textWhich decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, ni...2024-04-091h 00
Pharma Market Access Insights - from Petauri EvidenceNHS policy for 2024/25: strategy and engagement in a world of uncertainty (recorded in Jan 2024)Send us a textWhat do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Pa...2024-04-091h 02
Pharma Market Access Insights - from Petauri EvidenceEvidence strategy for Medical Technologies and DiagnosticsSend us a textHere, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?In this episode, our experts in HTA, health economics, and commercialisation explore:- How to...2024-03-1253 min
Pharma Market Access Insights - from Petauri EvidenceHow to set your Pharma or Medtech product up for success in the US marketSend us a textHow can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best support overarching product and brand strategy, with a focus on launch challenges in the US market.2024-02-2643 min
Pharma Market Access Insights - from Petauri EvidenceWhat's happening with specialised commissioning in the NHS?Send us a textWhat’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.Malcolm Qualie and David Thorne explored:Specialised commissioning in the NHSThe risks and opportunities that devolution to ICBs will bringWhat we ca...2024-02-121h 00